Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tekmira makes three appointments

This article was originally published in Scrip

Executive Summary

Tekmira Pharmaceuticals, a company focused on developing treatments for chronic hepatitis B virus infection (HBV), has made three executive appointments: Adam Cutler has been appointed senior vice-president, corporate affairs; Dr Bruce Dorsey has been appointed vice-president, chemistry; and Dr Rene Cornelis Rijnbrand has been named vice-president, Biology. Mr Cutler joins Tekmira from The Trout Group and Trout Capital. Before this he spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Banc of America Securities. Mr Dorsey was most recently vice-president of chemistry with OnCore Biopharma, focusing on HBV and building the company's US operations. Finally, Mr Rijnbrand joins Tekmira from OnCore Biopharma where he was vice-president and head of biology.

You may also be interested in...

A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts